|
1
|
Hu CM and Zhang L: Nanoparticle-based
combination therapy toward overcoming drug resistance in cancer.
Biochem Pharmacol. 83:1104–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang P, Wang D, Su Y, Huang W, Zhou Y,
Cui D, Zhu X and Yan D: Combination of small molecule prodrug and
nanodrug delivery: Amphiphilic drug-drug conjugate for cancer
therapy. J Am Chem Soc. 136:11748–11756. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saraswathy M and Gong S: Different
strategies to overcome multidrug resistance in cancer. Biotechnol
Adv. 31:1397–1407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo S, Lv L, Shen Y, Hu Z, He Q and Chen
X: A nanoparticulate pre-chemosensitizer for efficacious
chemotherapy of multidrug resistant breast cancer. Sci Rep.
6:214592016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li WM, Chiang CS, Huang WC, Su CW, Chiang
MY, Chen JY and Chen SY: Amifostine-conjugated pH-sensitive calcium
phosphate-covered magnetic-amphiphilic gelatin nanoparticles for
controlled intracellular dual drug release for dual-targeting in
HER-2-overexpressing breast cancer. J Control Release. 220:107–118.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan J, Mansour HM, Zhang Y, Deng X, Chen
Y, Wang J, Pan Y and Zhao J: Reversion of multidrug resistance by
co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl
cyanoacrylate) nanoparticles. Int J Pharm. 426:193–201. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sinha D, Biswas J, Sung B, Aggarwal BB and
Bishayee A: Chemopreventive and chemotherapeutic potential of
curcumin in breast cancer. Curr Drug Targets. 13:1799–1819. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mezzanotte L, An N, Mol IM, Löwik CW and
Kaijzel EL: A new multicolor bioluminescence imaging platform to
investigate NF-κB activity and apoptosis in human breast cancer
cells. PLoS One. 9:e855502014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aggarwal BB, Shishodia S, Takada Y,
Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin
suppresses the paclitaxel-induced nuclear factor-kappaB pathway in
breast cancer cells and inhibits lung metastasis of human breast
cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Angelini A, Iezzi M, Di Febbo C, Di Ilio
C, Cuccurullo F and Porreca E: Reversal of P-glycoprotein-mediated
multidrug resistance in human sarcoma MES-SA/Dx-5 cells by
nonsteroidal anti-inflammatory drugs. Oncol Rep. 20:731–735.
2008.PubMed/NCBI
|
|
11
|
Revalde JL, Li Y, Hawkins BC, Rosengren RJ
and Paxton JW: Heterocyclic cyclohexanone monocarbonyl analogs of
curcumin can inhibit the activity of ATP-binding cassette
transporters in cancer multidrug resistance. Biochem Pharmacol.
93:305–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou Q, Ye M, Lu Y, Zhang H, Chen Q, Huang
S and Su S: Curcumin improves the tumoricidal effect of mitomycin C
by suppressing ABCG2 expression in stem cell-like breast cancer
cells. PLoS One. 10:e01366942015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burgos-Morón E, Calderón-Montaño JM,
Salvador J, Robles A and López-Lázaro M: The dark side of curcumin.
Int J Cancer. 126:1771–1775. 2010.PubMed/NCBI
|
|
14
|
Cheng R, Meng F, Deng C, Klok HA and Zhong
Z: Dual and multi-stimuli responsive polymeric nanoparticles for
programmed site-specific drug delivery. Biomaterials. 34:3647–3657.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qian ZM, Li H, Sun H and Ho K: Targeted
drug delivery via the transferrin receptor-mediated endocytosis
pathway. Pharmacol Rev. 54:561–587. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Widera A, Norouziyan F and Shen WC:
Mechanisms of TfR-mediated transcytosis and sorting in epithelial
cells and applications toward drug delivery. Adv Drug Deliv Rev.
55:1439–1466. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mulik RS, Mönkkönen J, Juvonen RO, Mahadik
KR and Paradkar AR: Transferrin mediated solid lipid nanoparticles
containing curcumin: Enhanced in vitro anticancer activity by
induction of apoptosis. Int J Pharm. 398:190–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen S, Yang K, Tuguntaev RG, Mozhi A,
Zhang J, Wang PC and Liang XJ: Targeting tumor microenvironment
with PEG-based amphiphilic nanoparticles to overcome
chemoresistance. Nanomedicine. 12:269–286. 2016.PubMed/NCBI
|
|
19
|
Lin M, Teng L, Wang Y, Zhang J and Sun X:
Curcumin-guided nanotherapy: A lipid-based nanomedicine for
targeted drug delivery in breast cancer therapy. Drug Deliv.
23:1420–1425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao Z, Shao J, Tan B, Guan S, Liu Z, Zhao
Z, He F and Zhao J: Targeted lung cancer therapy: Preparation and
optimization of transferrin-decorated nanostructured lipid carriers
as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Int J Nanomed. 10:1223–1233. 2015. View Article : Google Scholar
|
|
21
|
Carlson LJ, Cote B, Alani AW and Rao DA:
Polymeric micellar co-delivery of resveratrol and curcumin to
mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci.
103:2315–2322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Yang C, Wang W, Liu J, Liu Q,
Huang F, Chu L, Gao H, Li C, Kong D, et al: Co-delivery of
doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for
combination therapy of cancer. Sci Rep. 6:212252016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao X, Chen Q, Li Y, Tang H, Liu W and
Yang X: Doxorubicin and curcumin co-delivery by lipid nanoparticles
for enhanced treatment of diethylnitrosamine-induced hepatocellular
carcinoma in mice. Eur J Pharm Biopharm. 93:27–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qu J, Zhang L, Chen Z, Mao G, Gao Z, Lai
X, Zhu X and Zhu J: Nanostructured lipid carriers, solid lipid
nanoparticles, and polymeric nanoparticles: Which kind of drug
delivery system is better for glioblastoma chemotherapy? Drug
Deliv. 08–Jun;2016.(Epub ahead of print). View Article : Google Scholar
|
|
25
|
Jelezova I, Drakalska E, Momekova D,
Shalimova N, Momekov G, Konstantinov S, Rangelov S and Pispas S:
Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized
drug delivery systems. Eur J Pharm Sci. 78:67–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang H, Murphy CJ, Zhang B, Shen Y, Van
Kirk EA, Murdoch WJ and Radosz M: Curcumin polymers as anticancer
conjugates. Biomaterials. 31:7139–7149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ling G, Zhang T, Zhang P, Sun J and He Z:
Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for
controlled delivery of mitoxantrone hydrochloride to enhance
anticancer activity bypassing the BCRP-mediated efflux. Drug Dev
Ind Pharm. 42:1351–1359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin L, Hutzen B, Zuo M, Ball S, Deangelis
S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, et al: Novel
STAT3 phosphorylation inhibitors exhibit potent growth-suppressive
activity in pancreatic and breast cancer cells. Cancer Res.
70:2445–2454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garbuzenko OB, Winkler J, Tomassone MS and
Minko T: Biodegradable Janus nanoparticles for local pulmonary
delivery of hydrophilic and hydrophobic molecules to the lungs.
Langmuir. 30:12941–12949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Misra R and Sahoo SK: Coformulation of
doxorubicin and curcumin in poly(D,L-lactide-co-glycolide)
nanoparticles suppresses the development of multidrug resistance in
K562 cells. Mol Pharm. 8:852–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu Y, Zhong Y, Meng F, Cheng R, Deng C and
Zhong Z: Acetal-linked paclitaxel prodrug micellar nanoparticles as
a versatile and potent platform for cancer therapy.
Biomacromolecules. 14:2772–2780. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou L, Liang D, He X, Li J, Tan H, Li J,
Fu Q and Gu Q: The degradation and biocompatibility of pH-sensitive
biodegradable polyurethanes for intracellular multifunctional
antitumor drug delivery. Biomaterials. 33:2734–2745. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bae Y, Jang WD, Nishiyama N, Fukushima S
and Kataoka K: Multifunctional polymeric micelles with
folate-mediated cancer cell targeting and pH-triggered drug
releasing properties for active intracellular drug delivery. Mol
Biosyst. 1:242–250. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee ES, Gao Z, Kim D, Park K, Kwon IC and
Bae YH: Super pH-sensitive multifunctional polymeric micelle for
tumor pHe specific TAT exposure and multidrug resistance. J Control
Release. 129:228–236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Li N, Nie Y, Sheng M, Yue D, Wang
G, Tang JZ and Gu Z: Folate-modified poly(malic acid) graft
polymeric nanoparticles for targeted delivery of doxorubicin:
Synthesis, characterization and folate receptor expressed cell
specificity. J Biomed Nanotechnol. 11:1628–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi H, Watanabe R and Choyke PL:
Improving conventional enhanced permeability and retention (EPR)
effects; what is the appropriate target? Theranostics. 4:81–89.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mei L, Fu L, Shi K, Zhang Q, Liu Y, Tang
J, Gao H, Zhang Z and He Q: Increased tumor targeted delivery using
a multistage liposome system functionalized with RGD, TAT and
cleavable PEG. Int J Pharm. 468:26–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nilsson C, Østergaard J, Larsen SW, Larsen
C, Urtti A and Yaghmur A: PEGylation of phytantriol-based lyotropic
liquid crystalline particles - the effect of lipid composition, PEG
chain length, and temperature on the internal nanostructure.
Langmuir. 30:6398–6407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang J, Zhang L, Gao H, Liu Y, Zhang Q,
Ran R, Zhang Z and He Q: Co-delivery of doxorubicin and P-gp
inhibitor by a reduction-sensitive liposome to overcome multidrug
resistance, enhance anti-tumor efficiency and reduce toxicity. Drug
Deliv. 23:1130–1143. 2016.PubMed/NCBI
|
